Carlo Pincelli

Company: PinCell

Job title: Chief Medical Officer

Seminars:

Disease Modification in Dermatology: A Novel, First in Class Targeted Therapy for the Non-Immunosuppressive Treatment of Pemphigus & Stevens-Johnson/Toxic Epidermal Necrolysis syndrome 1:00 pm

Development of a human monoclonal antibody against Fas ligand (PC111) that plays a major role in the pathogenesis of pemphigus and Stevens-Johnson/Toxic Epidermal Necrolysis syndrome Sharing recent data demonstrating targeted therapy, that acts downstream of the immune system, highly differentiates from currently used potent immunosuppressors, with a good safety profile, meeting patients’ satisfaction PC111 will…Read more

day: Day One